FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Insmed's Trailing 12-Month Free Cash Flow is MXN-16,876 Mil, and Market Cap is MXN423,780 Mil. Therefore, Insmed's FCF Yield % for today is -3.81%.
The historical rank and industry rank for Insmed's FCF Yield % or its related term are showing as below:
MEX:INSM'
s FCF Yield % Range Over the Past 10 Years
Min: -23.83 Med: -11.73 Max: -2.06
Current: -3.81
During the past 13 years, the highest FCF Yield % of Insmed was -2.06%. The lowest was -23.83%. And the median was -11.73%.
MEX:INSM's FCF Yield % is ranked better than 66.93% of 1409
companies
in the Biotechnology industry
Industry Median: -9.25
vs MEX:INSM: -3.81
Insmed's FCF Margin % for the quarter that ended in Mar. 2026 was -73.94%.
Insmed FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Insmed FCF Yield % Related Terms
Insmed FCF Yield % Historical Data
* Premium members only.
The historical data trend for Insmed's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INSM vs INCY, BNTX, ROIV: FCF Yield % Comparison
For the Biotechnology subindustry, Insmed's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Insmed's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (MEX:INSM) has a FCF Yield % of -3.81 as of Jul. 06, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Insmed and its competitors. According to the industry distribution chart, Insmed ranks #466 out of 1409 companies in the Biotechnology industry, placing it in the top 33.1%.
Is Insmed's FCF Yield % too high?
Insmed's current FCF Yield % is -3.81. Based on the distribution chart, Insmed ranks #466 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Insmed has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Insmed's FCF Yield % compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #466 out of 1409 companies for FCF Yield %. This puts Insmed in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Insmed and its competitors. Insmed's current FCF Yield % is -3.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Insmed (MEX:INSM) has a current FCF Yield % of -3.81. The stock's GF Value™ is MXN5,773.42, compared to a current price of MXN3,760.00 — trading 34.9% below its estimated fair value. The current FCF Yield % is -3.81. Insmed's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Insmed (MEX:INSM), the current FCF Yield % is -3.81 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MEX:INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of MXN3,760.00 is trading 34.9% below its estimated GF Value™ of MXN5,773.42.
Key valuation signals for MEX:INSM:
FCF Yield %: -3.81
GF Value™: MXN5,773.42 vs. price of MXN3,760.00 (34.9% below fair value)
No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
68GF Score
Get the complete analysis for MEX:INSM
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INSM has been successfully added to your 
